Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer communications

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

- PMLiVE

Succinct forms market access partnership with Royal Marsden

Agency aims is to tackle non-financial issues relating to new medicines

New marcomms agency opens in London’s Tech City

Couch is developing a client list from across pharma, private and public sectors

- PMLiVE

Merck KGaA starts third phase III trial for cancer hope TH-302

Unique method of action to target cells with low oxygen levels

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

Industry body recommends flexibility while economic pressures continue

HCA report highlights opportunity during financial uncertainty

- PMLiVE

Havas simplifies media operations

New structure part of its continued drive to put digital and content expertise at core

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

- PMLiVE

Janssen’s Zytiga approved for earlier use in Europe

Prostate cancer drug now licensed for use before chemotherapy

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links